David A. Siegel Nuvation Bio Inc. Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 533,900 shares of NUVB stock, worth $1.43 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

533,900

Previous 745,800 28.41%

Holding current value

$1.43 Million

Previous $2.18 Million 43.64%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$2.3 - $3.83 $487,369 - $811,577	-211,900 Reduced 28.41%	533,900 $1.23 Million
Q2 2024 Aug 14, 2024	SELL	$2.58 - $3.69 $703,824 - $1.01 Million	-272,800 Reduced 26.78%	745,800 $2.18 Million
Q1 2024 May 15, 2024	SELL	$1.46 - $3.97 $187,318 - $509,351	-128,300 Reduced 11.19%	1,018,600 $3.71 Million
Q4 2023 Feb 14, 2024	BUY	$0.96 - $1.53 $395,712 - $630,666	412,200 Added 56.1%	1,146,900 $1.73 Million
Q3 2023 Nov 14, 2023	BUY	$1.26 - $2.1 $100,170 - $166,950	79,500 Added 12.13%	734,700 $984,000
Q2 2023 Aug 14, 2023	BUY	$1.56 - $1.84 $42,120 - $49,680	27,000 Added 4.3%	655,200 $1.18 Million
Q1 2023 May 15, 2023	SELL	$1.6 - $2.48 $117,600 - $182,280	-73,500 Reduced 10.47%	628,200 $1.04 Million
Q4 2022 Feb 14, 2023	BUY	$1.68 - $2.5 $536,760 - $798,750	319,500 Added 83.59%	701,700 $1.35 Million
Q3 2022 Nov 14, 2022	BUY	$0.29 - $4.04 $76,415 - $1.06 Million	263,500 Added 221.99%	382,200 $856,000
Q2 2022 Aug 15, 2022	BUY	$3.24 - $5.85 $314,280 - $567,450	97,000 Added 447.0%	118,700 $385,000
Q1 2022 May 16, 2022	BUY	$4.6 - $8.83 $99,819 - $191,611	21,700 New	21,700 $114,000

Others Institutions Holding NUVB

# of Institutions

158

Shares Held

157M

Call Options Held

3.2K

Put Options Held

98.7K

View Full List

About Nuvation Bio Inc.

Ticker NUVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 217,244,000
Market Cap $582M
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...

More about NUVB

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account